2-bromoergocryptine
Bromocriptine
CAS: 25614-03-3
Molecular Formula: C32H40BrN5O5
2-bromoergocryptine - Names and Identifiers
2-bromoergocryptine - Physico-chemical Properties
| Molecular Formula | C32H40BrN5O5 |
| Molar Mass | 654.59 |
| Density | 1.2734 (rough estimate) |
| Melting Point | 215-218° (dec) |
| Boling Point | 891.3±65.0 °C(Predicted) |
| Water Solubility | 2.07mg/L(temperature not stated) |
| pKa | pKa 4.90±0.05(80% MCS t = RT) (Uncertain) |
| Refractive Index | 1.6400 (estimate) |
| Physical and Chemical Properties | Chemical properties white crystalline powder. Melting point 215-218 ℃ (decomposition). |
| Use | Uses the product has the Excitatory effect of dopamine receptors. Through the blood-brain barrier, into the central nervous system, dopamine receptor activation and inhibition of prolactin and growth hormone secretion. It is clinically used for Parkinson's disease, Acromegaly and galactorrhea. |
2-bromoergocryptine - Upstream Downstream Industry
2-bromoergocryptine - Nature
| specific rotation | D20 -195° (c = 1 in methylene chloride) |
Last Update：2024-04-10 22:29:15
2-bromoergocryptine - Uses and synthesis methods
overview
Bromocriptine is a specific dopamine receptor agonist of the hypothalamus and pituitary gland, which can directly act on the adenohypophysis and inhibit the secretion of prolactin. It is suitable for use in cycles using nolon derivatives.
production method
It is obtained by the reaction of ergocriptine and N-bromosuccinate imine.
category
Toxic substances
acute toxicity
High toxicity
stimulus data
intravenous-rat LD50: 72 mg/kg; Not reported-mouse LD50: 200 mg/kg
flammability hazard characteristics
Thermal decomposition discharges toxic nitrogen oxides and bromide fumes
storage and transportation features
Warehouse ventilation and dry low temperature
fire extinguishing agent
Water, carbon dioxide, sand, foam, dry powder
Last Update：2024-04-10 22:29:15
2-bromoergocryptine - Toxicity
An ergot alkaloid derivative that exhibits potent dopamine agonist properties, particularly at D2 dopamine receptors. Bromocriptine, like dopamine, inhibits prolactin release from the pituitary and so is used in endocrine disorders, such as hyperprolactinemia. It is also used in the treatment of Parkinson's disease. A large “first-pass” effect is seen with bromocriptine, and peak concentrations occur about 1.5-3 h after ingestion, with a half-life of about 3 h. Nausea, vomiting, and orthostatic hypotension are among the acute adverse effects. Long-term use has been associated with dyskinesias, constipation, psychoses, digital spasm, and erythromelalgia. The LD50 in rabbits exceeds 1 g/kg, p.o., and 12 mg/kg, I .v.
Last Update：2024-04-10 22:29:15
Supplier List
Product Name: Bromocriptine Visit Supplier Webpage Request for quotation
CAS: 25614-03-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 25614-03-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Bromocriptine Visit Supplier Webpage Request for quotation
CAS: 25614-03-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 25614-03-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History
Raw Materials for 2-bromoergocryptine